Genotyping protocol

Dpy19l3

IR00002736 / E103

(ICS internal reference)

This report has been prepared by: **Valérie Rousseau**
33 (0)3 88 65 56 55
genotyping@igbmc.fr

This report has been validated by: **Sylvie Jacquot, PhD, Head of Genotyping Service**
33 (0)3 88 65 57 44
genotyping @igbmc.fr

The first version of this report was finalized the: 11 Apr 2012

For any question, please contact:

Institut Clinique de la Souris - ICS - Mouse Clinical Institute
1 rue Laurent Fries, BP 10142
67404 Illkirch Cedex, France
Email: genotyping@igbmc.fr
Web site: http://www-mci.u-strasbg.fr/

TABLE OF CONTENTS

1. Genotyping protocol and data

This section describes the condition used at the Mouse Clinical Institute (ICS) to genotype your **Dpy19l3** Constitutive Knockout / Conditional Knockout (KO-cKO) project.

1.1. Genotyping strategy

The map below describes the position of the primers used for genotyping for each possible allele.



Sequence of primers used for genotyping:

Position	Primers	Sequence
Ef	4930	AGACAAGCTGGGATGAGGATTTAGCA
Ef[2]	4931	GGGGCCTGGCTTTTGGAACA
Er	4934	GACCTGGAGACTCTATGGAGAGACCCT
Kr	3209	CCAACAGCTTCCCCACAACGG
L3f	4936	GGCATGCTGACTCCTCTGCCCTG
L3f[2]	4933	CAAGGTAATCCCGGCAGCTACTGATGT
L3r	4935	CACAGGCACCAGGAACACATGTG
Lxr	4932	CGAAGTTATCATTAATTGCGTTGCGC

2. For a selected position, a second primer was designed

PCR fragments expected size (bp):

Region analyzed	Primers used	Position on the primer *(see the map above)*	Targeted allele (KO allele) (L3)	cKO allele (L2)	KO allele (L-)	WildType allele (WT)
5' part of the selection marker	4930-3209	Ef / Kr	468	---	---	---
Presence of the distal loxP	4936-4935	L3f / L3r	330	330	---	315
Distal loxP specific PCR	4933-4932	L3f[2] / Lxr	229	229	---	---
Excision of the selection marker	4931-4934	Ef[2] / Er	7413*	509	---	382
Excision of the floxed exon(s), i.e. knock out	4931-4935	Ef[2] / L3r	8068*	1164*	363**	1022*

*: this PCR product will not be observed using our PCR genotyping conditions (see description below)
**: this PCR is only verified if mice are generated
---: no Amplicon should be obtained

1.2. PCR protocol

This section describes the composition of the mix and cycling conditions used for genotyping.

Reagents:	Volume:
- FastStart PCR Master (Roche)	7.5µl
- DNA (50ng/µl)	1.5µl
- 5' primer (100 µM)	0.06µl
- 3' primer (100 µM)	0.06µl
- Sterile H_2O	up to 15 µl

Cycling conditions:

Temp	Time	#Cycles
95°C	4min	1
94°C	30s	
62°C	30s	34
72°C	1min	
72°C	7min	1
20°C	5min	1

NB: These PCR conditions have been optimized for high-throughput genotyping. Adaptation to small-scale may be required.

1.3. Picture of genotyping with various alleles

Analysis of PCR products pattern was not done by gel electrophoresis but using LabChip® 90 microfluidic apparatus. PCR products were run on the HT DNA 5K LabChip® 90 Assay Kit.

Representative genotyping picture



Note that as this technology is more sensitive than gel analysis, non specific signals and/or primer dimers may be visible on the picture.

2. Cre and Flp genotyping method

The protocol used to segregate the cre and/or flp transgene is indicated below.
Detection of cre transgene and flp transgene is done using a multiplex assay: primer pairs were designed for each gene and for a positive control (Cpxm1 gene).

2.1. Cre and Flp genotyping

Schematic representation of the genotyping strategy



Sequence of primers used for genotyping:

Primers	Sequence
4029	ACTGGGATCTTCGAACTCTTTGGAC
4030	GATGTTGGGGCACTGCTCATTCACC
4045	CCATCTGCCACCAGCCAG
4046	TCGCCATCTTCCAGCAGG
4195	TCTTTAGCGCAAGGGGTAGGATCG
4196	GTCCTGGCCACGGCAGAAGC

PCR fragments expected size (bp):

Primer pair	4045-4046	4195-4196	4029-4030
Region analyzed	Middle part of Cre transgene	Middle part of Flp transgene	Cpxm1 control gene
Control gene	/	/	446
Tg allele	281	328	/

2.2. PCR Protocol

This section describes the composition of the mix and cycling conditions used for genotyping.

Reagents	Volume
FastStart PCR Master (Roche)	7.5µl
DNA (50ng/µl)	1.5µl
5' primer (100 µM)	0.05µl
3' primer (100 µM)	0.05µl
Sterile H_2O	up to 15 µl

Cycling conditions are identical to those described in chapter 1.2